

# CITATION REPORT

List of articles citing

## Impaired fibrinolysis in coronary artery disease

DOI: 10.1016/0002-8703(88)90878-2  
American Heart Journal, 1988, 115, 776-80.

**Source:** <https://exaly.com/paper-pdf/19724469/citation-report.pdf>

**Version:** 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
118	Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. <b>1989</b> , 9, 362-7		187
117	Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors. <b>1989</b> , 31, 36-40		40
116	Clinical disorders of fibrinolysis: a critical review. <b>1989</b> , 59, 1-14		47
115	Inhibition of endothelial secretion of tissue-type plasminogen activator and its rapid inhibitor by agents which increase intracellular cyclic AMP. <b>1989</b> , 1012, 207-13		29
114	Platelet inhibitor agents in cardiovascular disease: an update. <b>1989</b> , 14, 813-36		129
113	The role of the fibrinolytic system in acute myocardial infarction after a normal exercise test. <b>1989</b> , 10, 1118-22		6
112	Reduced plasminogen activator inhibitor activity in high consumers of fruits, vegetables and root vegetables. <b>1990</b> , 227, 267-71		32
111	Plasma levels of endothelial-derived haemostatic factors in autoimmune thrombocytopenia and haemolytic anaemia. <b>1990</b> , 228, 249-52		6
110	Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease. <b>1990</b> , 20, 305-12		10
109	Reduced levels of tissue plasminogen activator and plasminogen activator inhibitor in plasma of patients with familial amyloidotic polyneuropathy. <b>1990</b> , 20, 31-6		
108	The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. <b>1990</b> , 16, 207-16		139
107	Relationship between plasminogen activator inhibitor activity and menopausal status. <b>1990</b> , 4, 233-236		12
106	Disorders of the hemostatic system and the risk of the development of thrombotic and cardiovascular diseases: limitations of laboratory diagnosis. <b>1990</b> , 163, 305-12		22
105	The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. <i>Clinica Chimica Acta</i> , <b>1990</b> , 188, 119-27	6.2	27
104	Clinical significance of plasminogen activator inhibitor activity in patients with exercise-induced ischemia. <i>American Heart Journal</i> , <b>1990</b> , 120, 831-8	4.9	27
103	A critical review of the relationship between impaired fibrinolysis and myocardial infarction. <i>American Heart Journal</i> , <b>1991</b> , 122, 545-51	4.9	52
102	Correlation of cross-linked fibrin degradation products (D-dimer) with coronary angiographic lesion morphology. <b>1991</b> , 30, 77-87		

101	Plasminogen activator inhibitor activity as a possible indicator of disease activity in rest angina with angiographically insignificant coronary artery stenosis. <b>1991</b> , 63, 491-502	9
100	Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. <b>1991</b> , 12, 157-61	161
99	Impaired fibrinolysis and risk of thromboembolism. <b>1991</b> , 34, 179-92	59
98	Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. <b>1991</b> , 229, 309-16	75
97	Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. <b>1991</b> , 34, 457-62	486
96	Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. <b>1991</b> , 40, 321-6	35
95	Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris. Does lipoprotein(a) alter fibrinolysis?. <b>1991</b> , 11, 1772-7	30
94	The role of fibrinolytic factors in ischaemia. <b>1991</b> , 5 ( Pt 2), 159-69	3
93	von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. <b>1991</b> , 66, 351-5	269
92	Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease. <b>1991</b> , 42, 561-7	4
91	Fish Oil and Vascular Disease. <b>1992</b> ,	2
90	Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsj�Sweden. <b>1992</b> , 13, 57-60	62
89	The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. <b>1992</b> , 95, 105-17	174
88	On the role of coagulation and fibrinolysis in atherosclerosis. <b>1992</b> , 2, 427-38	62
87	Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis. <b>1992</b> , 41, 2-6	17
86	Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis. <b>1992</b> , 22, 187-94	4
85	Hemostatic Factors in Ischemic Heart Disease and Stroke: Pathophysiologic Significance and Molecular Genetics. <b>1992</b> , 14, 237-252	
84	Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. <b>1993</b> , 36, 817-25	112

83	High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction. <b>1993</b> , 67, 237-44	8
82	Reactive oxygen intermediates and ischemia-reperfusion injury release tissue plasminogen activator from isolated rat hearts. <b>1993</b> , 71, 113-21	13
81	The hemostatic system and coronary heart disease. <b>1993</b> , 70, 1-38	92
80	The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. <b>1993</b> , 42, 945-9	193
79	Effect of a dietary copper deficiency on plasma fibrinolytic activity in male and female mice. <b>1993</b> , 13, 913-922	9
78	Insulin resistance and risk factors for coronary heart disease. <b>1993</b> , 7, 1063-78	59
77	Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. <b>1993</b> , 342, 1076-9	620
76	Increased plasma plasminogen activator inhibitor activity after coronary spasm. <b>1993</b> , 41, 21-9	11
75	Biological risk factors for restenosis after percutaneous transluminal coronary angioplasty. <b>1993</b> , 38, 7-18	17
74	Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. <b>1994</b> , 14, 1264-71	54
73	Fibrinolysis and thrombosis. <b>1994</b> , 7, 559-72	16
72	The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. <b>1994</b> , 8, 294-303	40
71	Validation of the Minnesota Leisure Time Physical Activity Questionnaire in Spanish men. The MARATHOM Investigators. <b>1994</b> , 139, 1197-209	348
70	Plasma fibrinogen as cardiovascular risk factor. <b>1995</b> , 38, 630-1	1
69	Analysis of plasma fibrinolysis in the patients with acute cerebral infarction. <b>1995</b> , 15, 68-72	
68	Diabetes and cardiovascular disease. The "common soil" hypothesis. <b>1995</b> , 44, 369-74	552
67	Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. <b>1995</b> , 45, 205-13	4
66	Hemostatic factors as triggers of cardiovascular events. <b>1996</b> , 14, 239-50	15

65	No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. <b>1996</b> , 45, 833-7		1
64	Cardiovascular risk factors and the prediabetic syndrome. <b>1996</b> , 28, 363-70		23
63	Plasminogen Activator Inhibitor 1 Is Elevated in the Children of Men with Premature Myocardial Infarction. <b>1996</b> , 76, 417-421		12
62	Characteristics and Treatment of Hypertension in Women: A Review of the Literature. <i>American Journal of the Medical Sciences</i> , <b>1996</b> , 311, 193-199	2.2	
61	Who Should Receive Hormone Replacement Therapy?. <b>1996</b> , 3, 13-21		6
60	Molecular markers of hemostasis and fibrinolysis and inhibitor levels in unstable angina pectoris. <b>1997</b> , 11, 61-65		
59	Fibrinolytic activity is not dependent upon exercise mode in post-myocardial infarction patients. <b>1998</b> , 78, 247-52		5
58	Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. <b>1998</b> , 12, 110-9		50
57	Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. <b>1998</b> , 31, 547-51		30
56	Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricular dysfunction. <b>1998</b> , 32, 1680-6		13
55	Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells. <b>1998</b> , 24, 151-6		8
54	Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1998</b> , 18, 244-9	9.4	63
53	Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).. <b>1998</b> , 1, 399		1
52	Rebound increase of plasminogen activator inhibitor type 1 after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. <b>1998</b> , 44, 209-214		15
51	Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 1378-86	9.4	27
50	Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 605-10	9.4	41
49	Correlation between coronary morphology and molecular markers of fibrinolysis in unstable angina pectoris. <b>1999</b> , 144, 151-7		13
48	Genetic modifiers of atherosclerosis in mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 2336-45	9.4	132

47	Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 846-52	9.4	73
46	Plasminogen-activator inhibitor type 1 and coronary artery disease. <b>2000</b> , 342, 1792-801		663
45	Infantile obesity: a situation of atherothrombotic risk?. <b>2000</b> , 49, 672-5		27
44	Myocardial Troponin T Release Is Associated with Enhanced Fibrinolysis in Patients with Acute Coronary Syndromes. <b>2001</b> , 86, 1176-1180		2
43	Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. <b>2001</b> , 12, 157-65		15
42	Stimulated release of endothelin-converting enzyme is simultaneous with tissue-type plasminogen activator and decrease in coronary heart disease. <b>2002</b> , 36, 100-4		6
41	Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. <b>2002</b> , 29, 441-9		70
40	Inhibition of PAI-1: a new anti-thrombotic approach. <b>2002</b> , 2, 27-42		30
39	Ozonized autohaemotransfusion and fibrinolytic balance in peripheral arterial occlusive disease. <b>2002</b> , 13, 671-81		8
38	Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. <b>2002</b> , 42, 1187-99		39
37	Association Between Increased Homocysteine Levels and Impaired Fibrinolytic Potential: Potential Mechanism for Cardiovascular Risk. <b>2002</b> , 88, 799-804		48
36	Increased levels of endothelial haemostatic markers in patients with coronary heart disease. <b>2002</b> , 105, 25-31		22
35	Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. <b>2002</b> , 21, 999-1008		29
34	Atherothrombotic risk factors in subjects with a family history of stroke. <b>2002</b> , 14, 153-60		12
33	Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. <b>2003</b> , 23, 1141-52		29
32	Increased plasma plasminogen activator inhibitor-1 levels: a possible marker of hypertensive target organ damage. <b>2003</b> , 25, 1-9		12
31	Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. <b>2003</b> , 89, 820-825		8
30	Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis. <b>2003</b> , 90, 710-6		11

29	Plasminogen activator inhibitor-1 promoter activity in adipocytes is not influenced by the 4 G/5 G promoter polymorphism and is regulated by a USF-1/2 binding site immediately preceding the polymorphic region. <b>2004</b> , 32, 155-63		6
28	The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension. <b>2004</b> , 58, 541-4		7
27	Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels. <i>Endocrine Research</i> , <b>2004</b> , 30, 443-53	1.9	12
26	The metabolic syndrome and inflammation. <b>2004</b> , 2, 82-104		144
25	An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. <b>2005</b> , 45, 30-4		34
24	Multiple biomarkers for the prediction of first major cardiovascular events and death. <b>2006</b> , 355, 2631-9		978
23	Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome. <b>2006</b> , 32, 1881-8		13
22	Bivalirudin for the Treatment of Heparin-Induced Thrombocytopenia. <b>2007</b> , 409-440		1
21	Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion. <b>2007</b> , 18, 165-71		10
20	Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?. <i>American Heart Journal</i> , <b>2007</b> , 154, 1059-64	4.9	18
19	Mechanisms of benefit of angiotensin receptor blockers in coronary atherosclerosis. <i>American Journal of the Medical Sciences</i> , <b>2008</b> , 336, 270-7	2.2	6
18	Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2009</b> , 57, 368-71	1.6	3
17	Plasminogen activator inhibitor-1, fibrinogen, and lung function in adolescents with asthma and obesity. <i>Endocrine Research</i> , <b>2012</b> , 37, 135-44	1.9	9
16	Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity. <i>International Journal of Endocrinology</i> , <b>2015</b> , 2015, 330185	2.7	10
15	Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011207	6	2
14	Metabolomics profiling and pathway analysis of human plasma and urine reveal further insights into the multifactorial nature of coronary artery disease. <i>Clinica Chimica Acta</i> , <b>2019</b> , 493, 112-122	6.2	9
13	Hemostatic risk factors for cardiovascular disease. <i>Developments in Cardiovascular Medicine</i> , <b>1996</b> , 135-151		1
12	Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. <i>American Journal of the Medical Sciences</i> , <b>1994</b> , 307, 317-24	2.2	9

11	Characteristics and treatment of hypertension in women: a review of the literature. <i>American Journal of the Medical Sciences</i> , <b>1996</b> , 311, 193-9	2.2	13
10	Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin. <i>Journal of Cardiovascular Pharmacology</i> , <b>1997</b> , 29, 337-42	3.1	8
9	Fibrinolytic activity is similar in physically active men with and without a history of myocardial infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 1106-13	9.4	10
8	Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. <i>Circulation</i> , <b>1995</b> , 91, 2520-7	16.7	92
7	Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. <i>Circulation</i> , <b>1995</b> , 91, 1952-8	16.7	185
6	Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. <i>Circulation</i> , <b>1997</b> , 95, 2380-6	16.7	62
5	Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. <i>Circulation</i> , <b>1997</b> , 95, 825-30	16.7	24
4	Epistatic interactions in genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. <i>PLoS ONE</i> , <b>2011</b> , 6, e16639	3.7	4
3	n-3 Fatty Acids and Fibrinolysis. <b>1992</b> , 73-77		
2	Fibrinolysefaktoren und Thrombogenese. <b>1999</b> , 525-527		
1	Gene expression of fibrinolytic markers in coronary thrombi.. <i>Thrombosis Journal</i> , <b>2022</b> , 20, 23	5.6	